MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.32
-0.04
-0.43%
After Hours: 9.32 0 0.00% 16:16 09/25 EDT
OPEN
9.30
PREV CLOSE
9.36
HIGH
9.49
LOW
9.00
VOLUME
568.34K
TURNOVER
--
52 WEEK HIGH
17.85
52 WEEK LOW
7.12
MARKET CAP
509.35M
P/E (TTM)
4.470
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Top Biotech Stocks for Q4 2020
These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.
Investopedia · 09/15 20:41
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 12:35
Vanda Pharma issues developmental plans for tradipitant
Vanda Pharmaceuticals (NASDAQ:VNDA) provides an update on its development program for tradipitant. Tradipitant is advancing in a Phase III study for the tr
Seeking Alpha - Article · 09/01 08:16
Vanda Pharmaceuticals Provides Update on Tradipitant Development Program
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant.
PR Newswire · 08/31 22:30
Vanda Pharmaceuticals: Plenty Of Upside Potential Here (And Limited Downside)
Vanda is an interesting investment opportunity with lots of pros and cons.The company markets Hetlioz and Fanapt in Non-24 sleep disorder and schizophrenia respectively, generating sales >$220m in FY19.There are nine further approvals in the offing for Hetlioz, Fanapt, and a third candidate, Tradipitant - all in late-stage trials.Vanda appears to have a difficult relationship with the FDA which has issued a complete response letter and refusal-to-file letter in recent years.Generic market entrants and ongoing legal cases are a threat, but I rate the company's peak sales opportunity to be $1bn-$1.5bn by 2025 and am bullish. A realistic share price target is ~$25.
Seekingalpha · 08/27 17:42
Unity Biotechnology Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Unity Biotechnology suffers setback for lead drug candidate UBX0101.ChromaDex reports positive Niagen news for heart failure.Vanda reports positive interim data from ODYSSEY study.
Seekingalpha · 08/20 17:05
Would Shareholders Who Purchased Vanda Pharmaceuticals'(NASDAQ:VNDA) Stock Three Years Be Happy With The Share price Today?
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the...
Simply Wall St. · 08/18 15:24
SRNE, DBX among premarket gainers
MICT (NASDAQ:MICT) +95% on first major order for SmartCam. Forward (NASDAQ:FORD) +49% on acquiring Kablooe Design. iMedia Brands (NASDAQ:IMBI) +26% on Q2 r
Seeking Alpha - Article · 08/18 12:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNDA. Analyze the recent business situations of Vanda Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNDA stock price target is 18.33 with a high estimate of 25.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 231
Institutional Holdings: 68.86M
% Owned: 126.00%
Shares Outstanding: 54.65M
TypeInstitutionsShares
Increased
64
5.27M
New
38
121.05K
Decreased
53
4.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Director
H. Thomas Watkins
Chief Executive Officer/President/Director
Mihael Polymeropoulos
Chief Financial Officer/Vice President/Treasurer
Kevin Moran
Senior Vice President/Chief Compliance Officer
Gian Piero Reverberi
Senior Vice President/Chief Compliance Officer
Gianpiero Reverberi
Senior Vice President/Chief Marketing Officer
Joakim Wijkstrom
Senior Vice President/General Counsel/Secretary
Timothy Williams
Senior Vice President
Gunther Birznieks
Other/IR Contact Officer
Aranthan Jones
Independent Director
Phaedra Chrousos
Independent Director
Richard Dugan
Independent Director
Stephen Mitchell
Independent Director
Anne Ward
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.